Trials / Completed
CompletedNCT00080262
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 125 (planned)
- Sponsor
- R-Pharm · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone | Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons. |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2004-03-26
- Last updated
- 2017-01-30
Locations
45 sites across 10 countries: United States, Argentina, Canada, France, Germany, Mexico, Netherlands, Norway, South Africa, Sweden
Source: ClinicalTrials.gov record NCT00080262. Inclusion in this directory is not an endorsement.